- Targeted Precision: Iza-Bren is an antibody-drug conjugate that identifies two specific proteins (EGFR and HER3) on cancer cells, delivering a toxic payload directly to the tumor while attempting to spare healthy tissue. The antibody recognizes these structures on the cell surface to transport the substance inside, where it disrupts DNA processing to trigger cell death.
- Superior Efficacy: In the Phase 3 trial, the risk of disease progression or death was reduced by 60 percent compared to traditional chemotherapy protocols. This translates to an additional 5.4 months of progression-free survival, a difference of nearly 95 percent.
- Safety Profile: The treatment is associated with a higher incidence of severe adverse events (79 percent) compared to standard chemotherapy (62 percent), necessitating careful clinical monitoring. Issues involving blood and blood formation were notably frequent.
As reported by the Frankfurter Rundschau, the drug functions by blocking growth-stimulating signals while simultaneously disrupting the cancer cell’s DNA processing, effectively triggering cell death.
The study involved 422 patients across 73 Chinese clinics who had previously failed third-generation EGFR inhibitor therapy. Among the cohort, 216 patients received Iza-Bren via infusion, while 206 were treated with chemotherapy agents including pemetrexed and either carboplatin or cisplatin.
Li Zhang of the Sun Yat-sen University Cancer Center noted that these findings suggest a potential shift in managing acquired resistance, a common challenge where tumors adapt to evade initial targeted therapies. He stated that the results could markieren einen wichtigen Wandel im Umgang mit erworbener Resistenz bei dieser Erkrankung
(mark an important change in dealing with acquired resistance in this disease).
While the progression-free survival metrics are promising, the clinical reality involves a trade-off regarding toxicity. The following table summarizes the comparative performance data for the drug Izalontamab Brengitecan versus chemotherapy, based on findings from a phase 3 clinical trial involving 422 patients:
,regionOfInterest=(86,652)&hash=8b4bc760df9fb588b77f201091d109cc393411ec9b6e5c4c255552f6caa1a35f "Photo: focus.de")
| Metric | Izalontamab Brengitecan | Standard Chemotherapy |
|---|---|---|
| Median Progression-Free Survival | 11.1 Months | 5.7 Months |
| Tumor Response Rate | ~60% | ~35% |
| Duration of Response | 10.4 Months | 5.7 Months |
| Severe Adverse Events | 79% | 62% |
| Treatment Discontinuation (Adverse) | 4 Patients | 4 Patients |
In each study arm, one patient died from treatment-related complications. Researchers are still investigating whether Iza-Bren increases overall survival, as current findings only show a favorable trend.
The underlying research was supported by the pharmaceutical companies SystImmune and Bristol Myers Squibb. These entities provided the clinical resources and data analysis for the Phase 3 trial.
